BR100 Increased By (0.9%)
BR30 Increased By (0.99%)
KSE100 Increased By (0.85%)
KSE30 Increased By (0.93%)
AGHA 6.47 Increased By ▲ 0.09 (1.41%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.50 Decreased By ▼ -0.05 (-0.08%)
BOP 31.52 Increased By ▲ 0.13 (0.41%)
CNERGY 11.78 Increased By ▲ 0.05 (0.43%)
CSIL 5.85 Decreased By ▼ -0.06 (-1.02%)
FCCL 61.82 Increased By ▲ 0.11 (0.18%)
FFL 15.02 Increased By ▲ 0.23 (1.56%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.33 Increased By ▲ 0.01 (0.16%)
KOSM 5.82 Decreased By ▼ -0.08 (-1.36%)
LOTCHEM 24.90 Increased By ▲ 0.21 (0.85%)
MLCF 105.86 Increased By ▲ 1.93 (1.86%)
NBP 174.77 Increased By ▲ 1.45 (0.84%)
NCPL 52.11 Increased By ▲ 0.28 (0.54%)
NPL 54.78 Increased By ▲ 0.75 (1.39%)
OGDC 318.99 Increased By ▲ 3.12 (0.99%)
PACE 9.32 Increased By ▲ 0.06 (0.65%)
PAEL 35.81 Increased By ▲ 0.23 (0.65%)
PIBTL 14.24 Increased By ▲ 0.58 (4.25%)
PPL 229.10 Increased By ▲ 3.03 (1.34%)
PRL 81.50 Increased By ▲ 1.22 (1.52%)
PTC 47.00 Increased By ▲ 0.36 (0.77%)
SSGC 24.01 Increased By ▲ 0.19 (0.8%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.67 Increased By ▲ 0.12 (1.59%)
TPL 24.85 Increased By ▲ 0.31 (1.26%)
TPLP 12.99 No Change ▼ 0.00 (0%)
TREET 25.91 Decreased By ▼ -0.07 (-0.27%)
TRG 53.73 Increased By ▲ 0.40 (0.75%)
By

PARIS: French pharmaceutical group Sanofi posted strong 2021 sales on Friday and expects another good performance in 2022, as the popularity of its asthma therapy offset setbacks in developing a Covid vaccine.

While Sanofi has yet to produce a jab against Covid, its Dupixent drug, which also treats eczema, has been a huge success, with the drug recording double-digit sales growth.

The company posted overall sales of 37.8 billion euros ($43.3 billion) in 2021, a 4.8 percent increase, according to its annual earnings statement.

Sanofi’s earnings per share (EPS) — a measure of a company’s profitability — rose by a better-than-expected 12 percent.

The company said it expects “low double-digit” growth of its EPS in 2022. EPS is a firm’s net profit divided by outstanding shares.

Comments

Comments are closed for this article.